-
Company Profile
Vascular Biogenics Ltd – Company Profile
Notable Labs Ltd (Notable Labs), formerly Vascular Biogenics Ltd, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene therapy medicines for the treatment of cancer and inflammatory diseases. Its lead product candidate VB-111, a gene-based biologic agent is developed to treat recurrent glioblastoma, colon, ovarian, thyroid cancer and solid tumors. Its pipeline products include VB 201 and VB 703, oral small molecules being developed through lecinoxoids platform for treating cardiovascular diseases, liver and renal fibrosis....
Add to Basket -
Sector Analysis
Gene Therapy Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Oncology Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene Induced Immunotherapy) and End-user (Hospitals, Diagnostic Centers, Research Institutes), 2022–2027
The gene therapy in oncology market size was valued at US$ 2,045 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.7% during 2022-2027. The key to the growth has been the high prevalence of cancer and growing demand for gene therapy over conventional therapies. Additionally, key strategic partnerships and mergers and acquisitions are expected to accelerate market growth. Over the forecast period, the market will witness an  increase in government support for...
-
Product Insights
Kidney Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Drugs In Development, 2022, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include...
-
Product Insights
Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colitis is swelling (inflammation) of the large intestine (colon). It can have many different causes, including infections including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders, lack of blood flow, or past radiation to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea, and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. The Colitis Drugs in Development market research report provides an overview of the colitis pipeline landscape....
-
Thematic Analysis
Gene Therapy in Oncology – Thematic Research
Gene therapy is the introduction of exogenous, genetic material into cells to treat a disease. Gene therapies provide therapeutic benefits to patients, especially those suffering from monogenic diseases. Cancers are generally not monogenic in origin, so gene therapies are more likely to be used to treat cancer by modifying gene regulation in tumorigenic pathways and expressing genes in cells that cause them to be recognized as foreign, or to elicit an immune response to tumorigenic cells. Sales of products that...
-
Sector Analysis
Gene Therapy in Oncology
Unlike conventional treatments such as chemotherapy, gene therapy combines reduced treatment duration (one time treatment in some cases) with higher chances of cure in oncology. This novel therapeutic approach requires direct delivery of genetic material to the patient or in vitro genetic modification of patient cells and subsequent delivery to the patient, which is an uncharted territory in oncology and will necessitate the implementation of new regulatory guidelines and restructuring of the existing treatment algorithms in various oncology indications. In...
-
Product Insights
Encephalomyelitis Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Encephalomyelitis Global Clinical Trials Review, H1, 2019" provides an overview of Encephalomyelitis clinical trials scenario. This report provides top line data relating to the clinical trials on Encephalomyelitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...